SERA Sera Prognostics, Inc.
USHealthcareAs of 2026-10-09 12:05
Why SERA matters now
Sera Prognostics, Inc. (SERA) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.03 with +0.50% on the session and $77.5M in market capitalization; recent performance reads 1-month +0.57% and YTD -40.68%.
The latest financial table shown here is Q1 2026, with revenue of $14.0K, net income of $-8.4M, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -41.3%.
The latest indexable market news headline is "1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It." from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Jackson Benjamin filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.30
P/S
1172.53
EV/EBITDA
-2.09
DCF Value
$-0.02
FCF Yield
-41.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-191.2%
Operating Margin
-64235.1%
Net Margin
-56386.0%
ROE
-41.0%
ROA
-34.4%
ROIC
-52.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $14.0K | $-8.4M | $-0.17 |
| Q4 2025 | $10.0K | $-7.9M | $-0.16 |
| FY 2025 | $81.0K | $-31.9M | $-0.67 |
| Q3 2025 | $16.0K | $-7.8M | $-0.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
0.94
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.